A new study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer. Results from the Phase III “ATLAS” trial have just been presented.
A new study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer. Results from the Phase III “ATLAS” trial have just been presented.